KCT0002166已完成未知
A Clinical Trial to Evaluate the Changes of Blood flow in Arterial anastomosis of Free flap after the Intraoperative administration of Alprostadil (Eglandin®) using Duplex ultrasonography in Patients who undergoing Free flap transfer
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 44
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational Study
入排标准
- 年龄范围
- 18(Year) 至 79(Year)（—）
- 性别
- All
入选标准
- •1. Plan to recieve free flap transfer under general anesthesia
- •2. Age: >=18 and <80 years old
- •3. Administration of alprostadil during surgery
- •4. Volunteer, who are provided written informed consent prior to study participation.
排除标准
- •1. Refuse the participation of study
- •2. >= American society of anesthesiologist physical status IV
- •3. History of diabetes mellitus
- •4. History of chronic renal failure
- •5. History of peripheral vascular disease or hyperlipidemia
- •6. Use of any vasopressor or inotropics for hemodynamic instability before participation of study
- •7. Inappropriate subjects who are identified by researchers
研究者
相似试验
进行中（未招募）
不适用
Evaluation of the pharmacodynamic effect of the combination of Sildenafil and Riociguat on blood pressure and other safety parametersMedDRA version: 14.1Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersPulmonary arterial hypertensionEUCTR2010-018863-40-DEBayer HealthCare AG18
进行中（未招募）
不适用
An interaction study to evaluate changes in blood pressure following 1, 1.5, 2, and 2.5 mg riociguat tid (dose titration) compared to placebo treatment on the background of stable sildenafil pretreatment in subjects with symptomatic pulmonary arterial hypertension - PATENT PLUSPulmonary arterial hypertension.MedDRA version: 9.1Level: LLTClassification code 10064911EUCTR2010-018863-40-ITBayer Health Care AG36
进行中（未招募）
不适用
Evaluation of the pharmacodynamic effect of the combination of Sildenafil and Riociguat on blood pressure and other safety parametersPulmonary arterial hypertensionMedDRA version: 14.1Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-018863-40-CZBayer HealthCare AG36
进行中（未招募）
不适用
Evaluation of the pharmacodynamic effect of the combination of Sildenafil and Riociguat on blood pressure and other safety parametersMedDRA version: 14.0Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersPulmonary arterial hypertensionEUCTR2010-018863-40-PLBayer HealthCare AG36
进行中（未招募）
不适用
An interaction study to evaluate changes in blood pressure following 1, 1.5, 2, and 2.5 mg riociguat tid (dose titration) compared to placebo treatment on the background of stable sildenafil pretreatment in subjects with symptomatic pulmonary arterial hypertension - PATENT PLUSMedDRA version: 12.1Level: LLTClassification code 10064911Term: Pulmonary arterial hypertensionPulmonary arterial hypertensionEUCTR2010-018863-40-ATBayer Health Care AG36